| Literature DB >> 28928711 |
Minh H Pham1,2, Morad Elshehabi1,3, Linda Haertner3,4, Silvia Del Din5, Karin Srulijes6, Tanja Heger3,4, Matthis Synofzik3,4, Markus A Hobert1,3, Gert S Faber7, Clint Hansen1, Dina Salkovic3, Joaquim J Ferreira8,9, Daniela Berg1,3, Álvaro Sanchez-Ferro10,11, Jaap H van Dieën7, Clemens Becker6, Lynn Rochester5,12, Gerhard Schmidt2, Walter Maetzler1,3.
Abstract
INTRODUCTION: Inertial measurement units (IMUs) positioned on various body locations allow detailed gait analysis even under unconstrained conditions. From a medical perspective, the assessment of vulnerable populations is of particular relevance, especially in the daily-life environment. Gait analysis algorithms need thorough validation, as many chronic diseases show specific and even unique gait patterns. The aim of this study was therefore to validate an acceleration-based step detection algorithm for patients with Parkinson's disease (PD) and older adults in both a lab-based and home-like environment.Entities:
Keywords: Parkinson’s disease; accelerometer; gait analysis; home-like activities; older adults; turning
Year: 2017 PMID: 28928711 PMCID: PMC5591331 DOI: 10.3389/fneur.2017.00457
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic and clinical data of the training and test groups.
| PD patients | Older adults | |||
|---|---|---|---|---|
| 3 (2) | 2 (1) | |||
| Age (years) | 72.3 (4.7) | 71.0 (2.8) | ||
| MDS-UPDRS III (0–132) | 26 (15) | 2 (2) | ||
| H&Y (0–5) | 2 (1) | 0 (0) | ||
| LED (mg) | 640 (353) | 0 (0) | ||
| 11 (5) | 12 (4) | |||
| Age (years) | 74.7 (7.2) | 70.8 (3.0) | ||
| MDS-UPDRS III (0–132) | 39 (9) | 1 (2) | ||
| H&Y (0–5) | 3 (1) | 0 (0) | ||
| LED (mg) | 540 (298) | 0 (0) | ||
| 4 (2) | 2 (1) | |||
| Age (years) | 69.3 (3.6) | 63.0 (17.0) | ||
| MDS-UPDRS III (0–132) | 20 (8) | 1 (0) | ||
| H&Y (0–5) | 2 (1) | 0 (0) | ||
| LED (mg) | 683 (735) | 0 (0) | ||
| 21 (11) | 12 (6) | |||
| Age (years) | 66.4 (9.0) | 58.4 (8.9) | ||
| MDS-UPDRS III (0–132) | 32 (12) | 2 (4) | ||
| H&Y (0–5) | 3 (1) | 0 (0) | ||
| LED (mg) | 841 (604) | 0 (0) | ||
Data are shown as mean ± SD, except gender.
H&Y, Hoehn and Yahr; LED, Levodopa equivalent dose; PD, Parkinson’s disease; MDS-UPDRS III, motor part of the revised Unified PD Rating scale.
Figure 1Experimental setting of the lab assessment showing the inertial measurement unit (IMU) position on the lower back, and the heel and toe markers to identify heel strike and toe off using the optoelectronic motion capture system.
Figure 2Heel strike (HS) and toe off (TO) detection using continuous wavelet transform (cwt) algorithm. IMU, inertial measurement unit; LPF, low-pass filter.
Figure 3(A) Heel strike (HS) and toe off (TO) were detected from the anterior–posterior (AP) coordinates of the heel and toe markers (gold standard). (B) Event detection from both feet, from AP acceleration (dashed line), its first-order differential continuous wavelet transform (dcwt) (dotted line, dcwt1) and its second-order dcwt (solid line, dcwt2). Black stars indicate HS, and black circles indicate TO. Dashed and solid vertical lines enable the comparison of the two methods to detect HS and TO, showing an overall good correspondence between them.
Figure 4(A) Bland–Altman plot illustrating the agreement for time of heel strike detection between the algorithm and the gold standard. The continuous line is the mean, and dashed lines are the 95% confidence intervals (CIs) of step observation difference (in seconds). (B) Bland–Altman plot illustrating the agreement for time of toe off detection between the algorithm and the gold standard. The continuous line represents the mean, and dashed lines are the 95% CI of step observation difference (in seconds). IMU, inertial measurement unit.
Validation values for steps detection in the home-like assessment.
| Cohorts | Cohen’s kappa (%) | Acc (%) | Sens (%) | Spec (%) | NPV (%) | PPV (%) | Steps detected by algorithm | Steps detected by clinical observers | True positive steps | False positive steps | False negative steps | True negative steps |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall cohort | 73 | 88 | 90 | 85 | 78 | 94 | 5,020 | 4,831 | 4,517 | 314 | 503 | 1,730 |
| PD patients | 70 | 88 | 90 | 83 | 75 | 94 | 3,618 | 3,484 | 3,257 | 227 | 361 | 1,083 |
| Controls | 77 | 89 | 90 | 88 | 82 | 94 | 1,402 | 1,347 | 1,260 | 87 | 142 | 647 |
| Overall cohort | 72 | 91 | 91 | 90 | 69 | 98 | 21,313 | 19,885 | 19,429 | 456 | 1,884 | 4,096 |
| PD patients | 71 | 91 | 91 | 90 | 67 | 98 | 15,522 | 14,493 | 14,181 | 312 | 1,341 | 2,738 |
| Controls | 74 | 91 | 91 | 90 | 71 | 97 | 5,791 | 5,392 | 5,248 | 144 | 543 | 1,358 |
Acc, accuracy; NPV, negative predictive value; PD, Parkinson’s disease; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.